Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing

S. J. Jacobsen, Slavica K Katusic, E. J. Bergstralh, J. E. Oesterling, D. Ohrt, G. G. Klee, C. G. Chute, M. M. Lieber

Research output: Contribution to journalArticle

185 Citations (Scopus)

Abstract

Objective. - To estimate the incidence of prostate cancer in Olmsted County, Minnesota, from 1983 through 1992 to describe the secular changes that have occurred since the introduction of serum prostate-specific antigen (PSA) testing to the community medical practice in 1987. Design. - Population-based, descriptive epidemiological study with ecologic and individual level comparisons over time. Study Setting. - Olmsted County, Minnesota, where the Rochester Epidemiology Project provides passive surveillance of the population for health outcomes. Subjects. - All 511 biopsy-proven incident cases of adenocarcinoma of the prostate diagnosed from 1983 through 1992. The community inpatient and outpatient medical records of all incident cases were reviewed to evaluate the presenting characteristics of men at the time of diagnosis. Results. - The age-adjusted incidence of biopsy-proven prostate cancer increased from 64 per 100 000 person-years in 1983 to 215 per 100 000 person-years in 1992. The increase occurred primarily between 1987 and 1988 and was predominately for organ-confined tumors. The age-specific incidence increased dramatically in this same period among men aged 50 years and older. Among men aged 70 years and older, however, prostate carcinoma incidence rates declined after 1990 following the initial increase. This decline among older men contrasted with community-based estimates of PSA utilization rates, which demonstrated consistent increases since 1987 to nearly 50% of the older population in 1992. Conclusion. - These results support the promise that the recent increase in prostate cancer is due in part to the increased utilization of serum PSA testing. Further, the increased incidence appears to be a transient phenomenon due to the depletion of previously undiagnosed cases from the prevalence pool. Finally, these data suggest that, in terms of stage at diagnosis, early detection efforts may be effective in identifying moro early stage (smaller) cancers.

Original languageEnglish (US)
Pages (from-to)1445-1449
Number of pages5
JournalJournal of the American Medical Association
Volume274
Issue number18
StatePublished - 1995

Fingerprint

Prostate-Specific Antigen
Prostatic Neoplasms
Incidence
Serum
Prostate
Population Surveillance
Biopsy
Population
Medical Records
Inpatients
Epidemiologic Studies
Neoplasms
Epidemiology
Adenocarcinoma
Outpatients
Carcinoma
Health

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Jacobsen, S. J., Katusic, S. K., Bergstralh, E. J., Oesterling, J. E., Ohrt, D., Klee, G. G., ... Lieber, M. M. (1995). Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. Journal of the American Medical Association, 274(18), 1445-1449.

Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. / Jacobsen, S. J.; Katusic, Slavica K; Bergstralh, E. J.; Oesterling, J. E.; Ohrt, D.; Klee, G. G.; Chute, C. G.; Lieber, M. M.

In: Journal of the American Medical Association, Vol. 274, No. 18, 1995, p. 1445-1449.

Research output: Contribution to journalArticle

Jacobsen, SJ, Katusic, SK, Bergstralh, EJ, Oesterling, JE, Ohrt, D, Klee, GG, Chute, CG & Lieber, MM 1995, 'Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing', Journal of the American Medical Association, vol. 274, no. 18, pp. 1445-1449.
Jacobsen, S. J. ; Katusic, Slavica K ; Bergstralh, E. J. ; Oesterling, J. E. ; Ohrt, D. ; Klee, G. G. ; Chute, C. G. ; Lieber, M. M. / Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. In: Journal of the American Medical Association. 1995 ; Vol. 274, No. 18. pp. 1445-1449.
@article{f019068e5d0743c0b770e4adabdb9e18,
title = "Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing",
abstract = "Objective. - To estimate the incidence of prostate cancer in Olmsted County, Minnesota, from 1983 through 1992 to describe the secular changes that have occurred since the introduction of serum prostate-specific antigen (PSA) testing to the community medical practice in 1987. Design. - Population-based, descriptive epidemiological study with ecologic and individual level comparisons over time. Study Setting. - Olmsted County, Minnesota, where the Rochester Epidemiology Project provides passive surveillance of the population for health outcomes. Subjects. - All 511 biopsy-proven incident cases of adenocarcinoma of the prostate diagnosed from 1983 through 1992. The community inpatient and outpatient medical records of all incident cases were reviewed to evaluate the presenting characteristics of men at the time of diagnosis. Results. - The age-adjusted incidence of biopsy-proven prostate cancer increased from 64 per 100 000 person-years in 1983 to 215 per 100 000 person-years in 1992. The increase occurred primarily between 1987 and 1988 and was predominately for organ-confined tumors. The age-specific incidence increased dramatically in this same period among men aged 50 years and older. Among men aged 70 years and older, however, prostate carcinoma incidence rates declined after 1990 following the initial increase. This decline among older men contrasted with community-based estimates of PSA utilization rates, which demonstrated consistent increases since 1987 to nearly 50{\%} of the older population in 1992. Conclusion. - These results support the promise that the recent increase in prostate cancer is due in part to the increased utilization of serum PSA testing. Further, the increased incidence appears to be a transient phenomenon due to the depletion of previously undiagnosed cases from the prevalence pool. Finally, these data suggest that, in terms of stage at diagnosis, early detection efforts may be effective in identifying moro early stage (smaller) cancers.",
author = "Jacobsen, {S. J.} and Katusic, {Slavica K} and Bergstralh, {E. J.} and Oesterling, {J. E.} and D. Ohrt and Klee, {G. G.} and Chute, {C. G.} and Lieber, {M. M.}",
year = "1995",
language = "English (US)",
volume = "274",
pages = "1445--1449",
journal = "JAMA - Journal of the American Medical Association",
issn = "0002-9955",
publisher = "American Medical Association",
number = "18",

}

TY - JOUR

T1 - Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing

AU - Jacobsen, S. J.

AU - Katusic, Slavica K

AU - Bergstralh, E. J.

AU - Oesterling, J. E.

AU - Ohrt, D.

AU - Klee, G. G.

AU - Chute, C. G.

AU - Lieber, M. M.

PY - 1995

Y1 - 1995

N2 - Objective. - To estimate the incidence of prostate cancer in Olmsted County, Minnesota, from 1983 through 1992 to describe the secular changes that have occurred since the introduction of serum prostate-specific antigen (PSA) testing to the community medical practice in 1987. Design. - Population-based, descriptive epidemiological study with ecologic and individual level comparisons over time. Study Setting. - Olmsted County, Minnesota, where the Rochester Epidemiology Project provides passive surveillance of the population for health outcomes. Subjects. - All 511 biopsy-proven incident cases of adenocarcinoma of the prostate diagnosed from 1983 through 1992. The community inpatient and outpatient medical records of all incident cases were reviewed to evaluate the presenting characteristics of men at the time of diagnosis. Results. - The age-adjusted incidence of biopsy-proven prostate cancer increased from 64 per 100 000 person-years in 1983 to 215 per 100 000 person-years in 1992. The increase occurred primarily between 1987 and 1988 and was predominately for organ-confined tumors. The age-specific incidence increased dramatically in this same period among men aged 50 years and older. Among men aged 70 years and older, however, prostate carcinoma incidence rates declined after 1990 following the initial increase. This decline among older men contrasted with community-based estimates of PSA utilization rates, which demonstrated consistent increases since 1987 to nearly 50% of the older population in 1992. Conclusion. - These results support the promise that the recent increase in prostate cancer is due in part to the increased utilization of serum PSA testing. Further, the increased incidence appears to be a transient phenomenon due to the depletion of previously undiagnosed cases from the prevalence pool. Finally, these data suggest that, in terms of stage at diagnosis, early detection efforts may be effective in identifying moro early stage (smaller) cancers.

AB - Objective. - To estimate the incidence of prostate cancer in Olmsted County, Minnesota, from 1983 through 1992 to describe the secular changes that have occurred since the introduction of serum prostate-specific antigen (PSA) testing to the community medical practice in 1987. Design. - Population-based, descriptive epidemiological study with ecologic and individual level comparisons over time. Study Setting. - Olmsted County, Minnesota, where the Rochester Epidemiology Project provides passive surveillance of the population for health outcomes. Subjects. - All 511 biopsy-proven incident cases of adenocarcinoma of the prostate diagnosed from 1983 through 1992. The community inpatient and outpatient medical records of all incident cases were reviewed to evaluate the presenting characteristics of men at the time of diagnosis. Results. - The age-adjusted incidence of biopsy-proven prostate cancer increased from 64 per 100 000 person-years in 1983 to 215 per 100 000 person-years in 1992. The increase occurred primarily between 1987 and 1988 and was predominately for organ-confined tumors. The age-specific incidence increased dramatically in this same period among men aged 50 years and older. Among men aged 70 years and older, however, prostate carcinoma incidence rates declined after 1990 following the initial increase. This decline among older men contrasted with community-based estimates of PSA utilization rates, which demonstrated consistent increases since 1987 to nearly 50% of the older population in 1992. Conclusion. - These results support the promise that the recent increase in prostate cancer is due in part to the increased utilization of serum PSA testing. Further, the increased incidence appears to be a transient phenomenon due to the depletion of previously undiagnosed cases from the prevalence pool. Finally, these data suggest that, in terms of stage at diagnosis, early detection efforts may be effective in identifying moro early stage (smaller) cancers.

UR - http://www.scopus.com/inward/record.url?scp=0028868908&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0028868908&partnerID=8YFLogxK

M3 - Article

C2 - 7474190

AN - SCOPUS:0028868908

VL - 274

SP - 1445

EP - 1449

JO - JAMA - Journal of the American Medical Association

JF - JAMA - Journal of the American Medical Association

SN - 0002-9955

IS - 18

ER -